Reneo Pharmaceuticals, Inc. (RPHM) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
18575 Jamboree Road
Irvine, CA 92612
United States of America (the)
Phone
619 733 3852
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
April 08, 2021
| Name | Title | Pay | Year Born |
| Gregory J. Flesher | President, Chief Executive Officer & Director | 569,704 | 1970 |
| Michael G. Grey | Founder & Executive Chairman | 100,000 | 1953 |
| Ashley F. Hall | Chief Development Officer | 447,104 | 1972 |
| Alejandro Dorenbaum | Chief Medical Officer | 466,229 | 1961 |
| Michael Cruse | Chief Operating Officer | 535,474 | 1972 |
| Jennifer Lam | SVice President of Finance & Administration and Principal Financial & Accounting Officer | 0 | N/A |
Reneo Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to creating therapies for individuals suffering from uncommon inherited mitochondrial disorders. The company's lead candidate, REN001, functions as a selective peroxisome proliferator-activated receptor delta agonist. This compound is currently undergoing Phase IIb clinical trials for patients with primary mitochondrial myopathies. Additionally, REN001 is being assessed in Phase 1b clinical trials for those diagnosed with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Founded in 2014, Reneo Pharmaceuticals' headquarters are located in San Diego, California.